ROYTANKY
voted
Spoiler:
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers! Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week! (Nano caps are excluded.)
Part Ⅰ: Make Your Choices
Part Ⅱ: Buzzing Stocks List & Mooers Comments
Three major indices moved upward, Russell 2000 Index increased 4.57...
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers! Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week! (Nano caps are excluded.)
Part Ⅰ: Make Your Choices
Part Ⅱ: Buzzing Stocks List & Mooers Comments
Three major indices moved upward, Russell 2000 Index increased 4.57...
![Weekly Buzz: meme-stock craze remains intact](https://ussnsimg.moomoo.com/77777000/editor_image/32910f4ef39434479ef8f7eb6acf2e7c.gif/thumb)
![Weekly Buzz: meme-stock craze remains intact](https://ussnsimg.moomoo.com/77777000/editor_image/1ae0598badbb3b95b3a26794b1fea995.png/thumb)
![Weekly Buzz: meme-stock craze remains intact](https://ussnsimg.moomoo.com/77777000/editor_image/4ef16590dfd03c7580a9fc78100ac889.png/thumb)
+2
57
34
ROYTANKY
commented on
The full FDA approval of Pfizer-BioNTech COVID-19 vaccine for age 16 and above is likely to give a boost to investors’ confidence in $Pfizer (PFE.US)$ and $BioNTech (BNTX.US)$ as it can lead to more people taking the vaccine. Pfizer-BioNTech enjoys a first mover advantage as its MRNA vaccine was the first to be issued EUA by FDA. With booster shots being advocated and more companies requiring their employees to be vaccinated, it can only mean more revenue.
Moderna is close behind as the second vaccine to receive the EUA from FDA. It has just completed submission to FDA tor full approval of the vaccine for age 18 and older. The stock price of $Moderna (MRNA.US)$ has rallied a lot recently due to it joining S&P 500 $SPDR S&P 500 ETF (SPY.US)$ so it remains to be seen whether it can still make new highs.
For the other vaccine stocks, the prospects may be less clear. As more countries try to develop their own local vaccines, the competition will become stiffer and the number of potential buyers may decrease.
The Oxford vaccine licensed by $AstraZeneca (AZN.US)$ has been mired in a number of controversies and it has yet to receive EUA from the FDA. There is word the company is reviewing the long term sustainability of the COVID-19 vaccine business.
$Novavax (NVAX.US)$ has received much interest in its non-MRNA vaccine but until it is rolled out, there may still be unknowns with regards to its performance and safety.
Last but not least, it is important to note that pharmaceutical business goes beyond the COVID-19 vaccine so the stock price can be affected by non-vaccine related developments.
Disclaimer: The above is not financial advice and should not be taken as a recommendation to invest. Please do your due diligence and consult your financial adviser before making any investment decision.
If you enjoy reading this article, you may also be interested in
“California Streaming” and Aapl’s Short Term Outlook https://www.moomoo.com/en-sg/community/feed/106924953829382?lang_code=2
Highest Returns To Date https://www.moomoo.com/en-sg/community/feed/106911175344134?lang_code=2
Great CEOs: Tim Cook and Steve Jobs https://www.moomoo.com/en-sg/community/feed/106837029355526?lang_code=2
Moderna is close behind as the second vaccine to receive the EUA from FDA. It has just completed submission to FDA tor full approval of the vaccine for age 18 and older. The stock price of $Moderna (MRNA.US)$ has rallied a lot recently due to it joining S&P 500 $SPDR S&P 500 ETF (SPY.US)$ so it remains to be seen whether it can still make new highs.
For the other vaccine stocks, the prospects may be less clear. As more countries try to develop their own local vaccines, the competition will become stiffer and the number of potential buyers may decrease.
The Oxford vaccine licensed by $AstraZeneca (AZN.US)$ has been mired in a number of controversies and it has yet to receive EUA from the FDA. There is word the company is reviewing the long term sustainability of the COVID-19 vaccine business.
$Novavax (NVAX.US)$ has received much interest in its non-MRNA vaccine but until it is rolled out, there may still be unknowns with regards to its performance and safety.
Last but not least, it is important to note that pharmaceutical business goes beyond the COVID-19 vaccine so the stock price can be affected by non-vaccine related developments.
Disclaimer: The above is not financial advice and should not be taken as a recommendation to invest. Please do your due diligence and consult your financial adviser before making any investment decision.
![My Opinion on Vaccine Stocks](https://ussnsimg.moomoo.com/moo-1629869620-101774928-iPhone-3-org.jpg/thumb)
![My Opinion on Vaccine Stocks](https://ussnsimg.moomoo.com/moo-1629870808-101774928-iPhone-5-org.jpg/thumb)
42
16